#United States #New York #Securities Fraud #Levi Korsinsky #Zenas BioPharma

Class Action Alert: Investors of Zenas BioPharma Targeted by Levi & Korsinsky

On April 25, 2025, Levi & Korsinsky, LLP issued a notification to investors regarding a class action lawsuit against Zenas BioPharma, Inc. (NASDAQ: ZBIO), highlighting serious allegations of securities fraud against the company. This announcement is particularly pertinent for those who purchased ZBIOS securities in connection with the company’s initial public offering (IPO) held in September 2024.

Understanding the Allegations

The core of the lawsuit revolves around claims that Zenas BioPharma’s management made substantial misstatements concerning the financial viability of the company. Specifically, the lawsuit alleges that the company overstated its ability to fund operations using available cash and anticipated net proceeds from the IPO. This has raised concerns among investors who now view the public statements issued by Zenas as misleading and not reflective of the company's true financial situation.

The filed complaint seeks to recover losses on behalf of Zenas BioPharma shareholders who have faced negative impacts due to what is suggested to be negligence from the company’s leadership. It is essential for affected investors to understand their rights under the law, and this lawsuit offers a pathway to seek potential financial recovery.

Key Details for Investors

For shareholders who suffered losses during the relevant timeframe, actions are required before the court's deadline of June 16, 2025. Specifically, interested investors have the opportunity to request that the Court appoint them as lead plaintiff, although this status is not needed to benefit from any recovery realized from the lawsuit.

Levi & Korsinsky emphasizes that if you are classified as part of the class, you could be entitled to financial restitution without incurring out-of-pocket expenses or fees. The firm assures that there is no cost or obligation attached to participation in this class action.

Experience and Support from Levi & Korsinsky

With a reputable history of obtaining settlements for shareholders over the last two decades, Levi & Korsinsky has established itself as a formidable player in securities litigation. The firm boasts a team of over 70 dedicated professionals who are experienced in handling complex investor claims and have a strong track record in high-stake cases. Notably, they have been recognized in ISS Securities Class Action Services' Top 50 Report as one of the premier securities litigation firms in the U.S. for seven consecutive years.

For investors who desire to learn more about their rights and the ongoing legal proceedings, Levi & Korsinsky encourages direct communication via email or phone. They provide resources and support tailored to assist aggrieved shareholders in navigating the complexities of securities law and the class action process.

Moving Forward

The outcome of the class action could set significant precedents in how securities fraud cases are litigated and handled within the investment community. Investors are encouraged to stay informed about this case as it progresses through the legal system. Those wishing to participate in the lawsuit should prepare to take timely action by meeting the specified deadlines and consulting with experienced legal professionals.

For more information on how to get involved, Zbio investors can fill out a contact form linked in the announcement or reach out to their legal team resources directly. It’s crucial for every aggrieved shareholder to consider their options carefully and act promptly to protect their investments.

In conclusion, the Zenas BioPharma lawsuit underscores the critical importance of accurate financial reporting and transparency from company management. Shareholders deserve to make informed decisions and, when necessary, seek recourse for any possible misrepresentation that might have adversely affected their financial investments.